ProKidney Corp. (PROK), a pioneer in the treatment of chronic kidney disease, is set to present full results from its Phase 2 REGEN-007 trial as a late-breaking clinical presentation at the American Society of Nephrology (ASN) 2025 Kidney Week, taking place from November 5 to 9, 2025, in Houston, Texas.
The data will spotlight the company's lead autologous cell therapy candidate, rilparencel, in patients with chronic kidney disease (CKD) and type 2 diabetes.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.